about
DYRK1A, a novel determinant of the methionine-homocysteine cycle in different mouse models overexpressing this Down-syndrome-associated kinaseTrisomy-21 gene dosage over-expression of miRNAs results in the haploinsufficiency of specific target proteinsDown's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1LDL receptor expression on T lymphocytes in old patients with Down syndromeIntegrative genomics identifies DSCR1 (RCAN1) as a novel NFAT-dependent mediator of phenotypic modulation in vascular smooth muscle cells.Stiffness of the large arteries in individuals with and without Down syndromeEarly-onset Moyamoya syndrome in a patient with Down syndrome: case report and review of the literature.Alzheimer's Disease in Down Syndrome.Understanding the basis for Down syndrome phenotypes.LDLR expression and localization are altered in mouse and human cell culture models of Alzheimer's diseaseAge-related changes in plasma levels of BDNF in Down syndrome patients.Toward onset prevention of cognitive decline in adults with Down syndrome (the TOP-COG study): study protocol for a randomized controlled trial.Total homocysteine and cardiovascular disease.Survival and morbidity outcomes for very low birth weight infants with Down syndromeA cross-sectional study of the phenotypes of obesity and insulin resistance in adults with down syndromeIs Apolipoprotein E4 an Important Risk Factor for Dementia in Persons with Down Syndrome?Risk of Major Cardiovascular Events in People with Down Syndrome.Sterol lipid metabolism in down syndrome revisited: down syndrome is associated with a selective reduction in serum brassicasterol levelsLipid profiles of children with Down syndrome compared with their siblings.Inter-Dependent Mechanisms Behind Cognitive Dysfunction, Vascular Biology and Alzheimer's Dementia in Down Syndrome: Multi-Faceted Roles of APPCerebrovascular contributions to aging and Alzheimer's disease in Down syndrome.(1)H-MRS metabolites in adults with Down syndrome: Effects of dementiaAn integrative computational analysis provides evidence for FBN1-associated network deregulation in trisomy 21Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.Towards onset prevention of cognition decline in adults with Down syndrome (The TOP-COG study): A pilot randomised controlled trialCardiovascular Disease, Single Nucleotide Polymorphisms; and the Renin Angiotensin System: Is There a MicroRNA Connection?Myocardial infarction in a patient with down syndrome: a case report and review of the literature.Atypical aging in Down syndrome.The effect of RCAN1 on the biological behaviors of small cell lung cancer.Body Composition and BMI Growth Charts in Children With Down SyndromeLow heart-type fatty acid binding protein level during aging may protect down syndrome people against atherosclerosis.Inflammatory and Immunological parameters in adults with Down syndromeHomocysteinaemia and coronary atherosclerosis.Cerebrovascular pathology in Down syndrome and Alzheimer disease.Does the association between serum endostatin, an endogenous anti-angiogenic protein, and acute myocardial infarction differ by race?Human cystathionine beta-synthase: gene organization and expression of different 5' alternative splicing.Atherosclerotic Surrogate Markers in Adults With Down Syndrome: A Case-Control Study.Down syndrome and microRNAs.Prevalence and incidence of myocardial infarction and cerebrovascular accident in ageing persons with intellectual disability.
P2860
Q21562345-2F3844FD-C98C-42C2-BDFD-C35C784D9482Q24622025-9B905025-9713-4B75-8F72-CA3532EC2DA0Q24654657-0670AE79-249E-4AC7-A0AF-DCE778E53E0DQ24792294-304486E8-54B6-47BE-BF98-E7A55E824BACQ30433341-258E188E-7AFF-4129-BB57-74672D72958BQ30474901-A4D21B2A-1C5F-4231-B42C-A7A393712814Q30619327-93B9A244-F857-41B6-9829-C969F6E483CFQ30857550-C9C59343-D4B7-45BB-94BC-37E836C1748FQ33238943-9350E469-1D37-458C-9DC1-63A4E607EC72Q33521909-2BADAE0E-4DF8-4E63-8FB8-4C64E479897FQ33738867-FFB5AB12-FD60-4D27-A5A1-D55F5F8F4619Q33770940-7408002E-684D-4454-9D9E-D181F1F57CF4Q33785883-281700AA-358A-43B1-9DC2-D805BE5C0659Q34689254-CE1C4EE9-FAF3-49BE-87BE-3B8DC0C8B3FCQ34750070-2F205D4B-7A69-4EC1-AA72-AF0858A6D75AQ34917679-F935DB72-8F2D-4682-AD6C-73C14F5BE27BQ35793298-A71B58F8-367E-4337-9B82-96B87031BBA7Q35977501-EF79326F-2CA8-47E1-A525-B2BB1377191DQ35996759-86EBFAA0-ECC9-4E8A-90C4-B3AF26FB93C6Q36332872-369A6B87-68EF-4B18-BDA5-E7F7019E3EACQ36767734-9ECC874D-F40A-4407-8C88-C3C29DC8A094Q37005407-B6A726C9-2891-4D18-B646-1AE56EE235C9Q37096595-5B858D65-745D-413B-837A-DAE896883048Q37102001-26E071B1-FD09-4B15-AF08-E057345AA982Q37139026-4D3458EF-1324-4AC7-8A32-A585427E096BQ37800362-982DEB7D-3E12-4018-A072-D6B307F302A9Q37836650-AE5B89B5-AB51-4193-918A-DCABEC5211E0Q38129325-2E2F3E1E-02D6-4368-B442-2F6AF10FF885Q38699703-535D2D40-8B2C-4E31-8D0B-DB2C46DFD2D5Q39388618-F75765E8-5D74-45CC-AB78-527A84C5B198Q42022577-040C917D-A320-4628-82E6-363296AEA26AQ42150452-6E0889BB-C929-41F6-9A66-BFE5E0A3DD44Q42390425-3A08A48F-6769-47E1-A0A8-CB7288E453E2Q46317444-186B2E59-3E38-4A8B-BC93-49DC61EA595CQ46413991-5B132CEA-75F0-4DF9-B5BF-C9E83D260A2DQ48042152-6FF6EAFB-F2C8-4D8F-B8ED-E1C3DFDD3E78Q48124681-BF72FE27-69CA-4BA8-BF12-74C178A19BF9Q49233869-606FEE22-3E37-4389-9063-66DCE9A942F7Q53099273-3C19D72C-03B9-4966-AC4C-8960503DFE2E
P2860
description
1977 nî lūn-bûn
@nan
1977年の論文
@ja
1977年学术文章
@wuu
1977年学术文章
@zh
1977年学术文章
@zh-cn
1977年学术文章
@zh-hans
1977年学术文章
@zh-my
1977年学术文章
@zh-sg
1977年學術文章
@yue
1977年學術文章
@zh-hant
name
Down's syndrome: an atheroma-free model?
@en
Down's syndrome: an atheroma-free model?
@nl
type
label
Down's syndrome: an atheroma-free model?
@en
Down's syndrome: an atheroma-free model?
@nl
prefLabel
Down's syndrome: an atheroma-free model?
@en
Down's syndrome: an atheroma-free model?
@nl
P2093
P356
P1433
P1476
Down's syndrome: an atheroma-free model?
@en
P2093
P304
P356
10.1136/BMJ.2.6081.226
P407
P577
1977-07-01T00:00:00Z